Abstract
Prostate cancer is the most common cancer among men and the second cause of male cancer-related deaths. There are currently three critical needs in prostate cancer imaging to personalize cancer treatment: (1) accurate intraprostatic imaging for multiple foci and extra-capsular extent; (2) monitoring local and systemic treatment response and predicting recurrence; and (3) more sensitive imaging of occult prostate cancer bone metastases. Recently, our lab developed porphysomes, inherently multimodal, all-organic nanoparticles with flexible and robust radiochemistry. Herein, we validate the first in vivo application of 64Cu-porphysomes in clinically relevant orthotopic prostate and bony metastatic cancer models. We demonstrate clear multimodal delineation of orthotopic tumors on both the macro- and the microscopic scales (using both PET and fluorescence) and sensitively detected small bony metastases (<2 mm). The unique and multifaceted properties of porphysomes offers a promising all-in-one prostate cancer imaging agent for tumor detection and treatment response/recurrence monitoring using both radionuclide- and photonic-based strategies.
Original language | English (US) |
---|---|
Pages (from-to) | 4221-4232 |
Number of pages | 12 |
Journal | ACS Nano |
Volume | 7 |
Issue number | 5 |
DOIs | |
State | Published - May 28 2013 |
Keywords
- orthotopic
- porphysomes
- prostate cancer
ASJC Scopus subject areas
- General Materials Science
- General Engineering
- General Physics and Astronomy